Summary
Stellar i-ris aims to prevent and reduce accidents on roads and at safety-critical workplaces due to users’ fatigue and narcotics (incl. alcohol, drugs, psychoactive medicine) intake. In the past 10 years, 376,343 fatal road accidents were reported in the EU. These accidents cause even more injuries and cost at the global level 1-3% of the world’s GDP. Occupational accidents cause 350,000 deaths /year and millions of serious injuries worldwide. It is estimated that drivers’ fatigue and narcotics intake cause approx. 27% of fatal road accidents. This has dramatic effects on our economy, society, infrastructure and healthcare systems. Yet for time and cost reasons, road users and safety-critical professions are tested very rarely. Scientifics estimate a high “hidden” number of cases of fatigue and driving under the influence (DUI) of narcotics. This is due to the absence of reliable, all-in-one tests on the market. No fatigue detection system is currently used by traffic authorities. The pupillary light reflex - a recognised marker for fatigue and narcotics - is one of the most relevant indicators. Current detection systems are not economically viable or present technical drawbacks (analysis time, accuracy, invasiveness, heavy equipment). Company Stellar offers the first non-invasive, reliable and quickest fatigue and narcotics detection system using a unique process and algorithm for the biometric measurement of the human pupil light reflex. It includes 2 product concepts: i-risHEAD, closed measurement glasses with IR-retina illumination, targeted to controllers (traffic authorities, OHS specialists, employers) and i-risLIGHT, a self-detection smartphone application, targeted to end users (drivers, workers at safety-critical workplaces). The innovation targets the markets of drug-of-abuse and fatigue testing in Europe – together estimated at €1 billion. Stellar i-ris will largely contribute to our company growth: €30M additional turnover and 87 new employees by 2023.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/805945 |
| Start date: | 01-03-2018 |
| End date: | 31-12-2020 |
| Total budget - Public funding: | 2 791 362,50 Euro - 1 953 953,00 Euro |
Cordis data
Original description
Stellar i-ris aims to prevent and reduce accidents on roads and at safety-critical workplaces due to users’ fatigue and narcotics (incl. alcohol, drugs, psychoactive medicine) intake. In the past 10 years, 376,343 fatal road accidents were reported in the EU. These accidents cause even more injuries and cost at the global level 1-3% of the world’s GDP. Occupational accidents cause 350,000 deaths /year and millions of serious injuries worldwide. It is estimated that drivers’ fatigue and narcotics intake cause approx. 27% of fatal road accidents. This has dramatic effects on our economy, society, infrastructure and healthcare systems. Yet for time and cost reasons, road users and safety-critical professions are tested very rarely. Scientifics estimate a high “hidden” number of cases of fatigue and driving under the influence (DUI) of narcotics. This is due to the absence of reliable, all-in-one tests on the market. No fatigue detection system is currently used by traffic authorities. The pupillary light reflex - a recognised marker for fatigue and narcotics - is one of the most relevant indicators. Current detection systems are not economically viable or present technical drawbacks (analysis time, accuracy, invasiveness, heavy equipment). Company Stellar offers the first non-invasive, reliable and quickest fatigue and narcotics detection system using a unique process and algorithm for the biometric measurement of the human pupil light reflex. It includes 2 product concepts: i-risHEAD, closed measurement glasses with IR-retina illumination, targeted to controllers (traffic authorities, OHS specialists, employers) and i-risLIGHT, a self-detection smartphone application, targeted to end users (drivers, workers at safety-critical workplaces). The innovation targets the markets of drug-of-abuse and fatigue testing in Europe – together estimated at €1 billion. Stellar i-ris will largely contribute to our company growth: €30M additional turnover and 87 new employees by 2023.Status
CLOSEDCall topic
SMEInst-13-2016-2017Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
